Cefovecin (Convenia®) is a new third generation cephalosporin antibiotic indicated for the treatment of bacterial skin diseases such as gingivitis, superficial pyoderma, subcutaneous infections (deep pyoderma), cellulitis and abscesses in dogs, caused by aerobic and anaerobic gram negative and gram positive bacteria.
Cefovecin is bactericidal against Staphylococcus pseudintermedius and Streptococcus spp, Escherichia coli, Pasteurella multocida, Klebsiella spp and Proteus spp, but is not active against Pseudomonas spp or Enterococcus spp. It is also effective against Bordetella spp, the causative organism of canine infectious tracheobronchitis.
Cefovecin has been formulated as an extended-spectrum cephalosporin solution containing 80 mg/ml cefovecin sodium, allowing extended therapeutic concentrations when given at 14-day intervals. It has a long half-life of 6.9 days and demonstrates prolonged concentrations in extracellular fluid allowing for dosing every 14 days. If required, the dose of 8 mg/kg subcutaneously in cats can be repeated every 14 days for a total of three doses. Cefovecin is eliminated through renal excretion with up to 25% biliary excretion, allowing it to be used in renal infections, prostatitis and cystitis.
Cefovecin should not be given to animals allergic to penicillins or cephalosporins, less than 8 weeks old, if they are pregnant or lactating, or have severe renal dysfunction.
Cefovecin was shown to be as effective as amoxicillin/clavulanate administered orally in the treatment of bacterial skin infections. Cefovecin offers the additional benefit of eliminating owner non-compliance.
The recommended dose for Cefovecin in cats is 8 mg/kg (0.1cc/kg) subcutaneously every 2 weeks for 3 doses.
- Van Vlaenderen I et al (2011) Estimation of the clinical and economic consequences of non-compliance with antimicrobial treatment of canine skin infections. Prev Vet Med 99(2-4):201-210
- Stegemann MR et al(2007) Clinical efficacy and safety of cefovecin in the treatment of canine pyoderma and wound infections. J Small Anim Pract 48(7):378-386
- Six R et al (2008) Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses, or infected wounds in dogs. J Am Vet Med Assoc 233(3):433-439
- Matousek, JL (2003) Infectious skin diseases. In Morgan, RV, Bright MR & Swartout, MS: Handbook of Small Animal Practise. 4th Edn. WB Saunders, Philadelphia. pp:842-857
- Westermeyer R et al (2010) In Vitro Comparison of Staphylococcus pseudintermedius Susceptibility to Common Cephalosporins Used in Dogs. Vet Ther 11(3):E1-9
- Stegemann, M. et al (2007) The efficacy and safety of cefovecin in the treatment of feline abscesses and infected wounds. J Small Anim Pract 48(12):683-89
- Murphy CP et al (2012) Out-patient antimicrobial drug use in dogs and cats for new disease events from community companion animal practices in Ontario. Can Vet J 53(3):291-298
- Stegemann MR et al (2006) Pharmacokinetics and pharmacodynamics of cefovecin in dogs. J Vet Pharmacol Ther 29(6):501-511
- Passmore CA et al (2007) Efficacy and safety of cefovecin (Convenia) for the treatment of urinary tract infections in dogs. J Small Anim Pract 48(3):139-144